News
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
TERACT - Résultats du 1er semestre 2025-2026
-
COMMUNIQUÉ DE PRESSE
Fourth quarter 2025 Results - EUR 208 million net income in Q4 2025, contributing to a strong full year net income of EUR 851 million - Proposed regular dividend of EUR 1.9 per share
SCOR SE reports EUR 208 million net income in Q4 2025, contributing to a strong full year net income of EUR 851 million. Proposed regular dividend of EUR 1.9 per share approved by the Board -
-
COMMUNIQUÉ DE PRESSE
Anja Hendel, Max Müller and Peter Schmid von Linstow to be nominated to the Supervisory Board of Redcare Pharmacy.
Anja Hendel, Max Müller and Peter Schmid von Linstow nominated to Redcare Pharmacy's Supervisory Board, enhancing expertise & strategic oversight. Björn Söder, Jérôme Cochet, Jaska de Bakker to step down -
-
COMMUNIQUÉ DE PRESSE
Redcare Pharmacy: Strong growth in 2025 surpassing EUR 1bn in Rx revenue; adj. EBITDA up 72% yoy.
Redcare Pharmacy reports strong growth in 2025, surpassing EUR 1bn in Rx revenue with adj. EBITDA up 72% yoy. Active customers grow to 13.9M. Guidance for 2026: 13%-15% revenue growth, adj. EBITDA margin 2.5% -
COMMUNIQUÉ DE PRESSE
Exercice 2025 – des résultats en hausse et des perspectives de croissance positives pour Implenia
Implenia AG affiche des résultats en hausse pour l'exercice 2025, avec un EBIT à CHF 140,5 millions et un carnet de commandes record à CHF 8,5 milliards, anticipant une croissance future -
COMMUNIQUÉ DE PRESSE
2025 financial year – Increased results and positive growth prospects for Implenia
Implenia AG reports improved operating profit and positive growth prospects for 2025 financial year with increased EBIT forecast for 2026 and proposed dividend hike. Details on order book, cash flow, personnel changes, and sustainability goals
